Next Article in Journal
Application of Response Surface Methodology to Improve the Tableting Properties of Poorly Compactable and High-Drug-Loading Canagliflozin Using Nano-Sized Colloidal Silica
Previous Article in Journal
The Other Side of Plastics: Bioplastic-Based Nanoparticles for Drug Delivery Systems in the Brain
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceutics
Volume 15
Issue 11
10.3390/pharmaceutics15112551
pharmaceutics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Chitosan Nanoparticles Loaded with Capparis cartilaginea Decne Extract: Insights into Characterization and Antigenotoxicity In Vivo

by
Asmaa S. Salman
1,2,
Shaza N. Alkhatib
1,
Fatimah M. Ahmed
1 and
Ragaa A. Hamouda
1,3,*
1
Biology Department, College of Science and Arts at Khulis, University of Jeddah, Jeddah 21959, Saudi Arabia
2
Genetic and Cytology Department, Biotechnology Research Institute, National Research Center, Cairo 12622, Egypt
3
Microbial Biotechnology Department, Genetic Engineering and Biotechnology Research Institute (GEBRI), University of Sadat City, Sadat City 32897, Egypt
*
Author to whom correspondence should be addressed.
Pharmaceutics 2023, 15(11), 2551; https://doi.org/10.3390/pharmaceutics15112551
Submission received: 26 September 2023 / Revised: 22 October 2023 / Accepted: 26 October 2023 / Published: 29 October 2023
(This article belongs to the Topic Challenges and Future Prospects of Antibacterial Therapy)
Browse Figures
Versions Notes

Abstract

:
Plant-based foods may enhance the prevention of cancer. The present investigation aimed to assess the antigenotoxic effects of chitosan nanoparticles (CNPs) when loaded with the ethanol extract of C. cartilaginea (CNPs/Cc). Synthesis of CNPs and CNPs/Cc and their characterization were carried out using TEM, EDS, DSC, and Zeta potential. For in vivo experiments, animal groups were treated in the following groups: negative control, ethyl methanesulfonate (EMS) (240 mg/kg), CNPs (350 mg/kg), high and low doses of CNPs/Cc, CNPs plus EMS, high dose of CNPs/Cc plus EMS, and low dose of CNPs/Cc plus EMS. Bone marrow chromosomal aberrations and sperm shape abnormalities were examined. TEM results showed that CNPs and CNPs/Cc are spherical particles. CNPs’ physical stability was observed to be lower than that of CNPs/Cc due to the presence of more positive charges on CNPs/Cc. EMS significantly enhanced chromosomal abnormalities and sperm shape abnormalities. CNPs showed powerful antigenotoxic properties. For the first time, it could be concluded that loading chitosan nanoparticles with C. cartilaginea extract significantly promotes its protective properties.

1. Introduction

Cancer is the second leading cause of death worldwide [1,2]. Environmental and dietary chemicals can induce endogenous and exogenous DNA damage, which is the first step in the process of carcinogenesis [3]. Given the relationship between food, nutrition, and cancer, plant-based diets have been reported to decrease overall cancer risk [4].
Medicinal plants with preventive and therapeutic properties play a vital role in healthcare systems. Capparaceae comprises a medium-sized family of about 45 genera and 700–900 species, whose members exhibit considerable variation in their habitat [5]. Capparis is the largest genus of Capparidaceae, comprising about 250–400 species of shrubs, trees, and woody climbers [6], represented by four species in Saudi Arabia. Capparis C. cartilaginea Decne is used in traditional medicine for treatment of various illnesses. These plants have shown different biological effects, including antioxidant, antihyperglycemic, hypolipidemic, and analgesic effects [7,8]. There is a growing body of literature that recognizes the immunostimulant, antitumoral, antidiabetic, antisclerotic, antimicrobial, anti-inflammatory, immunomodulatory, and antiviral activities of the Capparis species [9].
Currently, the development of new therapeutic drugs with improved efficiency is gaining much interest in the field of plant-based medicines. Nanoscale systems for drug delivery reduce the drug particles into the sub-micron range, thus enhancing the solubility, permeability, absorption, and bioavailability of their active ingredients [10]. One such system uses nanoparticles formed from chitosan, which is the second most abundant natural polymer after cellulose. Chitosan is a nontoxic, biocompatible, biodegradable, and cationic polysaccharide, which can be easily crosslinked with tripolyphosphate (TPP polyanions) under mild conditions to form nanoparticles [11,12]. The use of chitosan nanoparticles, with a tunable size and the possibility of surface modification, is a very promising and versatile strategy to overcome the bioavailability and stability issues of diverse natural active ingredients [13]. Chitosan-based nanosystems are among the most important and advanced drug delivery systems due to their remarkable physicochemical and biological characteristics. Thus, it has been widely used in the medical and pharmaceutical fields, and its potential as a drug carrier has been considered [14].
Ethyl methanesulfonate (EMS) is a dangerous chemical substance: it is mutagenic, teratogenic, and carcinogenic, and neither occurs naturally nor has any commercial uses. However, EMS is a known trace impurity in medications made of mesylate salts. Thus, it is regarded as an impurity rather than a contamination. EMS can cause gene mutations and chromosomal abnormalities through nucleotide substitution, especially through G:C-to-A:T transitions brought on by guanine alkylation [15,16,17]. In biochemical and medical research, EMS is generally utilized as a model alkylating agent, particularly in studies of DNA repair mechanisms. Usually, the mutations are severe loss-of-function or null alleles. Deletions or other chromosomal rearrangements account for around 13% of the EMS lesions [18].
Multiple phenotypes, metabolic byproducts, and biotic/abiotic stress tolerance are displayed in the EMS-induced mutants [19]. Guruprasad [20] observed that Brahmarasayana significantly reduced Ethylmethanesulfonate induced chromosomal aberrations in mouse bone marrow cells. The genotoxicity of EMS in mammals like mouse and rats was accomplished with changes in sperm morphology and limb defects in the embryos of pregnant rats [21].
Therefore, the present study aims to synthesize and characterize chitosan nanoparticles loaded with C. cartilaginea leaf extract and to establish whether loading chitosan nanoparticles with C. cartilaginea extract improves antigenotoxic activity against ethyl methanesulfonate (EMS)-induced genotoxicity in mice.

2. Materials and Methods

2.1. Materials

The leaves of C. cartilaginea were gathered in December 2021 from Al-Hada, Saudi Arabia, and were identified according to Chaudhary [22]. The chemicals used in this study were of analytical grade and used without further purification. Chemicals were purchased from the Saudi Chemical Company (PanReac AppliChem, Ar Riyad, Saudi Arabia).

2.1.1. Preparation of C. cartilaginea Leaf Extract

A total of 1031.0 g of C. cartilaginea leaves were cleaned and air-dried in the shade, then ground using a suitable grinder. The powdered leaves were soaked in absolute ethanol for 72 h. The extract was filtered, then evaporated using a rotary evaporator (IKA RV 8 Basic V-C, Leicestershire, UK). The leaf extract was lyophilized using a freeze-drying lyophilizer until complete dryness was achieved and preserved at −20 °C. The residue yield was 8.2% of C. cartilaginea.

2.1.2. C. cartilaginea Characterization

The characterization of C. cartilaginea was performed via Fourier-transform infrared spectroscopy (FTIR) using a Thermo Fisher Nicolet IS10 (Waltham, MA, USA) spectrometer.

GC–MS Analysis

The method of GC–MS analysis was used on the plant according to Rautela et al. [23].

2.2. Synthesis and Optimization Process of CNPs/Cc

2.2.1. Synthesis of CNPs

Chitosan was obtained from Sigma-Aldrich. The ionic gelation of CNPs was conducted as described by Masarudin et al. [24]. Three grams of chitosan (medium molecular weight) was mixed with 10 mL of 1.0% acetic acid, and then 990 mL of distilled water was added to the mixture. The solution was stirred using a magnetic stirrer for 2 h to dissolve the chitosan. For the cross-linker, 1 g of TPP was dissolved in 1 L of distilled water at pH 5.0. This was added to the chitosan solution and stirred continuously with a magnetic stirrer until complete dissolution. The mixture was centrifuged at 5000× g for 20 min, washed, and then lyophilized until complete dryness (Figure 1).

2.2.2. Synthesis of CNPs/Cc

CNPs and CNPs/Cc were synthesized according to Masarudin et al. [24]. Three grams of chitosan (medium molecular weight) was dissolved in 10 mL of 1.0% acetic acid, then 990 mL of distilled water was added. The chitosan solution was stirred using a magnetic stirrer for two hours to guarantee complete dissolution. The plant extract (3 g) was dissolved in 100 mL of dimethyl sulfoxide (DMSO, purity ≥ 99.5%), using a magnetic stirrer to ensure that the plant extract was completely dissolved. For the cross-linker, 1 g of TPP was dissolved in 900 mL of distilled water at pH 5.0. TPP solution and plant extract were mixed and added drop-by-drop to the dissolved chitosan, then stirred for two hours. The mixture was refined by centrifugation for 20 min at 5000 rpm, then washed three times with distilled water, followed by lyophilization until it was completely dry (Figure 2). This extract was used for pharmacological testing.

2.2.3. Characterization of CNPs and CNPs/Cc

Characterization of CNPs and CNPs/Cc was accomplished using an FTIR (Waltham, MA, USA) Spectrometer, Thermo Fisher Nicolet IS10, to produce the FTIR spectrum (4000 and 400 cm−1). The size and morphology of the nanoparticles at the nanoscale were characterized by means of transmission electron microscopy (TEM) (JEOL JSM-6510/v, Tokyo, Japan). The chemical contents of nanoparticles were determined via energy-dispersive spectroscopy (EDS) (JEOL JSM-6510/v, Tokyo, Japan), and a Zeta potential analyzer was used to determine the surface charge and stability [25] (Malvern Zeta size Nano-Zs90, Malvern, PA, USA). Thermographic analysis was performed via differential scanning calorimetry (DSC) testing of 5–10 mg using a DSC131 EVO (Lyon, France).

2.3. In Vivo Antigenotoxicity

2.3.1. Experimental Animals

Male SWR mice (9–12 weeks old, 25–27 g each) were obtained from the Animal House Colony at King Fahad Medical Research Centre. Animals were kept in plastic cages under normal conditions of a night–day cycle (12/12 h). Food and water were supplied ad libitum.
Animals were kept in artificially illuminated (12 h dark/light cycle) and thermally controlled (25 ± 1 °C) conditions. Humane care was applied to all animal groups in compliance with the guidelines of the Animal Care and Use Committee of the University of Jeddah (Approval # UJ-21-DR-41).

2.3.2. Experimental Design

Animals were divided into the groups listed in Table 1.

2.3.3. Chromosome Abnormalities Assay

Chromosomal aberration was assessed as described by Moore et al. [26]. For this, animals were injected i.p. with colchicine, 2 h before sacrifice. The method of Yosida and Amano [27] was applied in bone marrow chromosome preparations. One hundred metaphases were examined per animal, and the metaphases with aberrations such as gaps, chromosome or chromatid breakage, and fragments were recognized.

2.3.4. Sperm Morphology Assay

Rasgele’s sperm morphology testing was carried out [28]. Cauda epididymides were crushed in an isotonic sodium citrate solution. Sperms were smeared on slides, fixed, and stained with Eosin Y. In total, 1000 sperms were examined per animal. The head and tail abnormalities of sperm were detected.

2.4. Statistical Analysis

All data are provided as mean values with standard deviations (SDs) based on five replicates and probability values (p ≤ 0.05). Tukey’s method and one-way ANOVA (version 16) were used to evaluate the significance of data.

3. Results and Discussion

3.1. Fourier-Transform Infrared Spectroscopy (FTIR)

FTIR was performed to compare the functional groups of the C. cartilaginea extract, the CNPs, and the CNPs/Cc. In total, eight band regions were observed in C. cartilaginea (3231, 2924, 1598, 1508, 1396, 1267, 1038, and 614), in the CNPs (3335, 2126, 1636, 1558, 1540, 1457, 1096, and 623 cm−1), and in the CNPs/Cc (3346, 2132, 1636, 1540, 1418, 1077, 1011, and 950). The results showed similarity between the chemical structures of CNPs and CNPs/Cc; the wavenumber 1636 was the peak in the CNPs/Cc, and the CNPs presented CHO stretching of the carbonyl group, typical saccharide absorption, and a peak of 1540 cm−1, which relates to the amide groups that are present in chitosan (Table 2 and Figure 3).

3.2. GC–MS Analysis of C. cartilaginea Extract

The GC–MS analysis of Capparis cartilaginea showed the presence of 15 compounds (Figure 4). The prevailing compounds were 9,12,15-octadecatrienoic acid, methyl ester (14.99%); Hexadecanoic acid, methyl ester (11.79%); D-Pyroglutamic acid (9.03), hydroxy-bicyclo[3.3.1]n on-2-en-9-one (6.15%); 7-hydroxy-bicyclo[3.3.1]n on-2-en-9-one (4.25%); octadecanoic acid, methyl ester (3.24%); CIS-5,8,11,14,17-eicosapentaenoic acid (3.22%); 9-octadecenoic acid (z)- hexadecanoic ACID (3.21%); hexadecanoic acid, ethyl ester (3.09%); 2-aminoethanethiol hydrogen sulfate (ester) (2.98%); 9-octadecenoic ACID (Z)- 2-aminoethanethiol (2.91%); 9,12-Oetadecadienoyl chloride, (Z,Z)- (2.76%); 9-Octadecenoic acid (Z)-, methyl ester (2.09%); acethydrazide, n2-[1-(2,3-dihydro-6-methyl pyran-2-yl)ethylideno]- (2.05%); 3,5-Heptadienal and 2-ethylidene-6-methyl (2.00%). All these compounds are bioactive and possess many activities such as antibacterial, anticancer, antiviral, and antioxidant, as presented in Table 3.

3.3. Zeta Potential Characterization

Zeta potential determination is a crucial method for characterizing the surface charge and comprehending the physical stability of nanosuspensions [50]. The nanoparticles examined in this investigation had surfaces that were positively charged (Figure 5a,b). The results showed that the particles generated in this investigation were comparable to those described in the literature [51,52,53,54,55,56]. The CNPs/Cc had a zeta potential of about +34.49 mV (Figure 5a), while the CNPs had a zeta potential of about +52.78 mV (Figure 5b). This showed the CNPs/Cc’s incipient instability and the CNPs’ moderate stability. The positive surface charges of chitosan were affected by the addition of bioactive components, altering the stability of the nanoparticles. If the value of the zeta potential ranges between 0 and ±5 mV, it is an indicator of rapid coagulation; ±10 to ±30 mV indicates incipient instability; ±30 to ±40 mV indicates moderate stability; ±40 to ±60 mV indicates good stability; and >±61 mV indicates excellent stability [57].

3.4. TEM Analysis

A TEM micrograph showed the CNPs to have a spherical particle shape (Figure 6a) and a size range of 9–25 nm [54,56,58], the CNPs/Cc had a spherical shape and a size range of 18–30.1 nm (Figure 6b). The size difference between the CNPs and the CNPs/Cc may be due to the effect of the plant extract being loaded with nanoparticles. Using cross-linked chitosan is necessary to have better control over its shape and size [59]. The TEM image showed the aggregation of the chitosan nanoparticles [60]. The chitosan nanoparticles appeared as tiny and individual spheres, with a diameter ranging from 30 to 40 nm. Larger particles are caused by the aggregation of single tiny particles that manage to fuse, producing a larger entity [61,62].

3.5. Energy-Dispersive Spectroscopy (EDS)

Figure 7a,b depict the EDS analysis of the CNPs and the CNPs/Cc. The EDS of the CNPs revealed a high-intensity metallic peak of elements such as oxygen (O) with an atomic weight of 52.72%, 37.82% for carbon (C), 8.37% for phosphate (P), and low-intensity peaks of aluminum (Al). The EDS of the CNPs/Cc also confirmed the presence of carbon with an atomic weight of 30.40%, 49.72% for oxygen, 13.83% for nitrogen, 3.91% for phosphate, and low-intensity peaks of aluminum (Al), sodium (Na), and sulfur (S). It was possible to observe an increase in the intensities of the C and O signals relative to the other metals’ signals, which was likely caused by the chitosan nanoparticles [28]. EDS was employed to confirm the presence of TPP as cross-linked junctions in the CS particles, by monitoring the content of phosphorus in CS-TPP [63]. New signals of Na and P were obtained in the CNPs/Cc samples, due to the cross-linking of TPP with CS [64].

3.6. Differential Scanning Calorimetry (DSC)

Figure 8 shows the DSC thermogram of the CNPs and the CNPs/Cc. The temperature ranged from 20 to 600 °C. A sharp endothermic peak was observed between 75.60 and 186.73 °C, showing the nanoparticles’ potential for heat breakdown. The exothermic peak of the CNP at 196.82 and 219.39.73 °C followed by an exothermic peak at 219.91 and 256.44 °C could be due to water evaporation. The CNPs exhibited a sharp endothermic peak at 45.46 and 163.82, after a tiny endothermic peak at 169.23 and 207.41, while an exothermic peak was observed at 214.66 and 247.90 °C. The result is in agreement with Yousef et al. [65], whose DSC thermogram of chitosan showed an endothermic peak at 180 °C and an exothermic peak at 370 °C. Chitosan DSC thermogram showed two peaks. The loss of water molecules was connected to the first one (endothermic, below 100 °C); the second signal, which was exothermic and occured at a temperature of about 300 °C, was connected to the breakdown of the chitosan pyranose ring [66,67]. The results showed that exothermic peaks, also known as crystallization peaks, were present throughout the DSC analyses’ heating scan [25].

3.7. Chromosomal Aberrations Observed in Bone Marrow Cells

Table 4 presents the number and percent of chromosomal aberrations in control and treatment animals. Treatment with EMS induced a significant increase in chromosomal aberrations in the bone marrow cells, reaching 24.4% (p < 0.01). The present results are in agreement with the findings of Norizadeh Tazehkand et al. [68], who documented that treatment of mice with 240 mg/kg EMS significantly increased chromosomal aberrations. There are large and diverse groups of chemicals that can induce DNA damage, and they are classified as carcinogens. Humans maybe exposed to these substances directly or indirectly in the environment or through diet. EMS has a potential negative effect, including cancer, aberrant birth outcomes, and heritable impacts, which are seen as natural consequences of its genotoxic activity [69]. EMS is an alkylating agent commonly used as a positive agent in genotoxicity studies [70] with the potential to cause cancer by altering DNA nucleotides, resulting in point mutations as the initial G:C base pair undergoes a mutation to A:T during replication base-pair insertions or deletions [71].
No significant aberrations were observed in the animal groups treated with CNPs or CNPs/Cc at their low tested doses. Moreover, pretreatment with CNPs/Cc at two tested doses for seven days succeeded in reducing (p < 0.01) the EMS-induced abnormalities significantly in a dose-dependent manner. The percentage of reduction reached 36.06% and 59.01% after treatment with low and high doses of CNPs/Cc, respectively (Table 4). Nanocurcumin and nanochitosan have antioxidant and antigenotoxic properties against the toxicity of potassium dichromate [72]. Salix subserrata bark extract-loaded chitosan nanoparticles exhibited promising potent neuroprotective and antioxidative efficiencies against arsenic-induced oxidative threats [73].

3.8. Sperm Shape Abnormalities

As shown in Table 5, male mice exposed to EMS developed defective sperm in a statistically highly significant (p < 0.01) percentage that reached 14.44%. The most prevalent anomalies were triangular, amorphous, and lacking hook heads and coiled tails. Chromosomal aberrations, testicular DNA alterations, and point mutations may contribute to the induction of sperm shape abnormalities [28].
The percentage of aberrant sperm was decreased when mice were treated with cCNP and CNPs simultaneously, reaching 10.02, 9.7, and 7.26% (p < 0.01). Following the treatment of mice with LD cCNP, HD cCNP and CNPs, the percentage of reduction reached 30.6, and 32.8, 49.7%. A previous study proved that pre-treatment with ZnO-Alg/NCMs for seven days significantly reduced chromosomal aberrations in somatic cells and spermatocytes and reduced the percentage of morphological sperm abnormalities [74].
Several studies on the phytochemistry of the genus Capparis have revealed the presence of terpenoids, flavonoids, alkaloids, glucosinolates, isothiocyanates, sterols, and fatty acids in various plant sections [9]. The methanol extract of Capparis cartilaginea leaves contains seven types of antioxidants [75] that could inhibit various human oxidative stress pathologies and possess DNA-protective attributes [76]. According to Moharram et al. [77], the anti-inflammatory activity is probably due to the antioxidant active constituents of the plant such as flavonoids, alkaloids, phenolic, coumarins, and tannin compounds.
Many recent studies emphasized the utilization of nanoparticles as a phytochemical carrier molecule to improve their solubility, bio-accessibility, and cellular bioavailability [78,79]. Several studies proved the protective capabilities of chitosan nanoparticles. Abdel-Wahhab et al. [80] demonstrated that chitosan nanoparticles modulate DNA fragmentation and suppress mycotoxin-induced genotoxicity in rats. The antioxidant and antigenotoxic properties of chitosan nanoparticles against potassium-dichromate-induced toxicity in male albino mice were documented by Mohamed et al. [72].

4. Conclusions

CNPs were synthesized, loaded with C. cartilaginea extract, and investigated via Fourier-transform infrared spectroscopy. The Zeta potential analyses proved that CNPs/Cc are more positively charged than CNPs. In vivo experiments illustrated that oral treatment with CNPs and CNPs/Cc is safe. Moreover, chitosan nanoparticles showed powerful antigenotoxic properties. Loading the chitosan nanoparticles with C. cartilaginea extract greatly improved their anticancer properties, mainly due to the plant’s active constituents and the small nanoparticle size that encouraged its cellular bioavailability.

Author Contributions

This work was carried out through the collaboration of all authors. Author A.S.S. wrote the protocol, carried out the experimental work of the genetic part, analyzed the study data, managed the literature searches, and wrote the final draft of the manuscript. Author S.N.A. carried out the experimental work, writing, and review. Author F.M.A. performed the statistical analysis, carried out the experimental work of plant materials, nanoparticle synthesis and characterization, and the in vivo part of the work. Author R.A.H. carried out the experimental work and analyses of nanoparticle synthesis and characterization and managed the literature searches. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The animal study protocol was approved by the Animal Care and Use Committee of the University of Jeddah (Approval # UJ-21-DR-41).

Informed Consent Statement

Not applicable.

Data Availability Statement

The datasets used and/or analyzed during this study are available from the corresponding author on reasonable request.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Barnes, J.L.; Zubair, M.; John, K.; Poirier, M.C.; Martin, F.L. Carcinogens and DNA damage. Biochem. Soc. Trans. 2018, 46, 1213–1224. [Google Scholar] [PubMed]
  2. Bray, F.; Laversanne, M.; Weiderpass, E.; Soerjomataram, I. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer 2021, 127, 3029–3030. [Google Scholar] [CrossRef] [PubMed]
  3. Basu, A.K. DNA damage, mutagenesis, and cancer. Int. J. Mol. Sci. 2018, 19, 970. [Google Scholar] [CrossRef] [PubMed]
  4. DeClercq, V.; Nearing, J.T.; Sweeney, E. Plant-based diets and cancer risk: What is the evidence? Curr. Nutr. Rep. 2022, 11, 354–369. [Google Scholar]
  5. Alshehri, K.M. Anticancer Plants Naturally Growing in Al-Baha Region, Saudi Arabia. Int. J. Pharm. Res. Allied Sci. 2020, 9, 92–101. [Google Scholar]
  6. Inocencio, C.; Rivera, D.; Obón, M.C.; Alcaraz, F.; Barreña, J.A. A systematic revision of capparis section Capparis (Capparaceae). Ann. Mo. Bot. Gard. 2006, 93, 122–149. [Google Scholar] [CrossRef]
  7. Eddouks, M.; Lemhadri, A.; Michel, J.B. Hypolipidemic activity of aqueous extract of Capparis spinosa L. in normal and diabetic rats. J. Ethnopharmacol. 2005, 98, 345–350. [Google Scholar] [CrossRef]
  8. Ghule, B.; Murugananthan, G.; Yeole, P. Analgesic and antipyretic effects of Capparis zeylanica leaves. Fitoterapia 2007, 78, 365–369. [Google Scholar] [CrossRef]
  9. Tlili, N.; Elfalleh, W.; Saadaoui, E.; Khaldi, A.; Triki, S.; Nasri, N. The caper (Capparis L.): Ethnopharmacology, phytochemical and pharmacological properties. Fitoterapia 2011, 82, 93–101. [Google Scholar]
  10. Peltonen, L.; Hirvonen, J. Drug nanocrystals–versatile option for formulation of poorly soluble materials. Int. J. Pharm. 2018, 537, 73–83. [Google Scholar]
  11. Aghili-Khorasani, H.; Makhzan, A. Source of Plant Research Institute for Islamic and complementary medicine Press. Iran Univ. Med. Sci. 2008, 729, 30. [Google Scholar]
  12. Soutter, W. Chitosan Nanoparticles—Properties and Applications, 2nd ed.; AZoNano: Sydney, Australia, 2013. [Google Scholar]
  13. Mohammed, M.A.; Syeda, J.T.; Wasan, K.M.; Wasan, E.K. An overview of chitosan nanoparticles and its application in non-parenteral drug delivery. Pharmaceutics 2017, 9, 53. [Google Scholar] [CrossRef]
  14. Sharifi-Rad, J.; Quispe, C.; Butnariu, M.; Rotariu, L.S.; Sytar, O.; Sestito, S.; Rapposelli, S.; Akram, M.; Iqbal, M.; Krishna, A.; et al. Chitosan nanoparticles as a promising tool in nanomedicine with particular emphasis on oncological treatment. Cancer Cell Int. 2021, 21, 318. [Google Scholar] [CrossRef]
  15. Jacinto, F.V.; Esteller, M. MGMT hypermethylation: A prognostic foe, a predictive friend. DNA Repair 2007, 6, 1155–1160. [Google Scholar] [CrossRef] [PubMed]
  16. Gerber, C.; Toelle, H.-G. What happened: The chemistry side of the incident with EMS contamination in Viracept tablets. Toxicol. Lett. 2009, 190, 248–253. [Google Scholar] [CrossRef] [PubMed]
  17. Flibotte, S.; Edgley, M.L.; Chaudhry, I.; Taylor, J.; Neil, S.E.; Rogula, A.; Zapf, R.; Hirst, M.; Butterfield, Y.; Jones, S.J.; et al. Whole-genome profiling of mutagenesis in Caenorhabditis elegans. Genetics 2010, 185, 431–441. [Google Scholar] [CrossRef] [PubMed]
  18. Anderson, P. Mutagenesis. Methods Cell Biol. 1995, 48, 31–58. [Google Scholar] [PubMed]
  19. Saito, T.; Ariizumi, T.; Okabe, Y.; Asamizu, E.; Hiwasa-Tanase, K.; Fukuda, N.; Mizoguchi, T.; Yamazaki, Y.; Aoki, K.; Ezura, H. TOMATOMA: A novel tomato mutant database distributing Micro-Tom mutant collections. Plant Cell Physiol. 2011, 52, 283–296. [Google Scholar] [CrossRef]
  20. Guruprasad, K.P.; Subramanian, A.; Singh, V.J.; Sharma, R.S.K.; Gopinath, P.M.; Sewram, V.; Satyamoorthy, K. Brahmarasayana protects against Ethyl methanesulfonate or Methyl methanesulfonate induced chromosomal aberrations in mouse bone marrow cells. BMC Complement. Altern. Med. 2012, 12, 113. [Google Scholar] [CrossRef]
  21. Kurniadi, A.S.; Irawati, F.; Putra, S.E.D.; Hardjo, P.H. Induction of Protocorm-Like Bodies (PLBs) Phalaenopsis spp. Hybrids Mutation through Ultraviolet Irradiation (UV254) and Ethyl Methane Sulfonate (EMS). Agriprima J. Appl. Agric. Sci. 2023, 7, 1–15. [Google Scholar] [CrossRef]
  22. Chaudhary, S.A. Flora of the Kingdom of Saudi Arabia, 2nd ed.; Ministry of Agriculture & Water: Riyadh, Saudi Arabia, 2001; pp. 455–457. [Google Scholar]
  23. Rautela, I.; Dheer, P.; Thapliyal, P.; Joshi, T.; Sharma, N.; Sharma, M.D. GC-MS analysis of plant leaf extract of Datura stramonium in different solvent system. Eur. J. Biomed. Pharm. Sci. 2018, 5, 236–245. [Google Scholar]
  24. Masarudin, M.J.; Cutts, S.M.; Evison, B.J.; Phillips, D.R.; Pigram, P.J. Factors determining the stability, size distribution, and cellular accumulation of small, monodisperse chitosan nanoparticles as candidate vectors for anticancer drug delivery: Application to the passive encapsulation of [14C]-doxorubicin. Nanotechnol. Sci. Appl. 2015, 8, 67–80. [Google Scholar] [CrossRef]
  25. Iglesias-Montes, M.L.; Soccio, M.; Siracusa, V.; Gazzano, M.; Lotti, N.; Cyras, V.P.; Manfredi, L.B. Chitin nanocomposite based on plasticized poly (lactic acid)/poly (3-hydroxybutyrate) (PLA/PHB) blends as fully biodegradable packaging materials. Polymers 2022, 14, 3177. [Google Scholar] [CrossRef] [PubMed]
  26. Moore, P.D.; Patlolla, A.K.; Tchounwou, P.B. Cytogenetic evaluation of malathion-induced toxicity in Sprague-Dawley rats. Mutat. Res./Genet. Toxicol. Environ. Mutagen. 2011, 725, 78–82. [Google Scholar] [CrossRef] [PubMed]
  27. Yosida, T.H.; Amano, K. Autosomal polymorphism in laboratory bred and wild Norway rats, Rattus norvegicus, found in Misima. Chromosoma 1965, 16, 658–667. [Google Scholar] [CrossRef] [PubMed]
  28. Rasgele, P.G. Abnormal sperm morphology in mouse germ cells after short-term exposures to acetamiprid, propineb, and their mixture. Arh. Hig. Rada Toksikol. 2014, 65, 47–55. [Google Scholar] [CrossRef]
  29. Tokarek, K.; Hueso, J.L.; Kuśtrowski, P.; Stochel, G.; Kyzioł, A. Green synthesis of chitosan-stabilized copper nanoparticles. Eur. J. Inorg. Chem. 2013, 2013, 4940–4947. [Google Scholar] [CrossRef]
  30. Wang, B.; Song, Y.; Zhang, X.; Chen, K.; Liu, M.; Hu, X.; He, L.; Huang, Q. Polymer derived SiBCN (O) ceramics with tunable element content. Ceram. Int. 2022, 48, 10280–10287. [Google Scholar] [CrossRef]
  31. Talari, A.C.S.; Martinez, M.A.G.; Movasaghi, Z.; Rehman, S.; Rehman, I.U. Advances in Fourier transform infrared (FTIR) spectroscopy of biological tissues. Appl. Spectrosc. Rev. 2017, 52, 456–506. [Google Scholar] [CrossRef]
  32. Umamaheswari, S.; Murali, M. FTIR spectroscopic study of fungal degradation of poly (ethylene terephthalate) and polystyrene foam. Chem. Eng. 2013, 64, 159. [Google Scholar]
  33. Trivedi, M.; Branton, A.; Trivedi, D.; Shettigar, H.; Bairwa, K.; Jana, S. Fourier transform infrared and ultraviolet-visible spectroscopic characterization of biofield treated salicylic acid and sparfloxacin. Nat. Prod. Chem. Res. 2015, 3, 1000186. [Google Scholar] [CrossRef]
  34. Shi, J.; Xing, D.; Lia, J. FTIR studies of the changes in wood chemistry from wood forming tissue under inclined treatment. Energy Procedia 2012, 16, 758–762. [Google Scholar] [CrossRef]
  35. Bianchi, C.L.; Stucchi, M.; Pirola, C.; Cerrato, G.; Sacchi, B.; Vitali, S.; Di Michele, A.; Capucci, V. Micro-sized TiO2 catalyst in powder form and as coating on porcelain grès tile for the photodegradation of phenol as model pollutant for water phase. Adv. Mater. Sci. 2017, 2, 1–6. [Google Scholar] [CrossRef]
  36. Sahoo, S.; Chakraborti, C.K.; Mishra, S.C.; Nanda, U.; Naik, S. FTIR and XRD investigations of some fluoroquinolones. Int. J. Pharm. Pharm. Sci. 2011, 3, 165–170. [Google Scholar]
  37. Volkov, D.S.; Rogova, O.B.; Proskurnin, M.A. Organic matter and mineral composition of silicate soils: FTIR comparison study by photoacoustic, diffuse reflectance, and attenuated total reflection modalities. Agronomy 2021, 11, 1879. [Google Scholar] [CrossRef]
  38. Dutta, S.; Ray, S.; Nagarajan, K. Glutamic acid as anticancer agent: An overview. Saudi Pharm. J. 2013, 21, 337–343. [Google Scholar] [CrossRef] [PubMed]
  39. Aslam, S.; Wang, F.; Ahmad, M.; Zahoor, A.F.; Mansha, A.; Rasul, A.; Fu, L. Benzothiazine based acetohydrazides and acetamides as anticancer agents. Pak. J. Pharm. Sci. 2019, 32, 2795–2800. [Google Scholar]
  40. Maduabuchi, E.K.; Tobechukwu, O.P. Advanced phytochemistry and chemo-metric profiling of the bioactive medicinal components of n-hexane seed extract of Xylopia aethiopica using FTIR and GC-MS techniques. GSC Biol. Pharm. Sci. 2023, 22, 247–256. [Google Scholar] [CrossRef]
  41. Jan, N.; Andrabi, K.I.; John, R. Calendula officinalis—An important medicinal plant with potential biological properties. Proc. Indian Natl. Sci. Acad. 2017, 83, 769–787. [Google Scholar]
  42. Qanash, H.; Yahya, R.; Bakri, M.M.; Bazaid, A.S.; Qanash, S.; Shater, A.F.; TM, A. Anticancer, antioxidant, antiviral and antimicrobial activities of Kei Apple (Dovyalis caffra) fruit. Sci. Rep. 2022, 12, 5914. [Google Scholar] [CrossRef]
  43. Vijayabaskar, G.; Elango, V. Determination of phytocompounds in Withania somnifera and Smilax China using GC-MS technique. J. Pharmacogn. Phytochem. 2018, 7, 554–557. [Google Scholar]
  44. Sumathi, R. GC-MS Analysis of Methanol Extracts of Flowers of Allamanda neriifolia Hook. Indian J. Curr. Res. 2015, 2, 49–53. [Google Scholar]
  45. Mujeeb, F.; Bajpai, P.; Pathak, N. Phytochemical evaluation, antimicrobial activity, and determination of bioactive components from leaves of Aegle marmelos. BioMed Res. Int. 2014, 2014, 497606. [Google Scholar] [CrossRef] [PubMed]
  46. Awa, E.P.; Ibrahim, S.; Ameh, D.A. GC/MS analysis and antimicrobial activity of diethyl ether fraction of methanolic extract from the stem bark of Annona senegalensis Pers. Int. J. Pharm. Sci. Res. 2012, 3, 4213–4218. [Google Scholar]
  47. Belakhdar, G.; Benjouad, A.; Abdennebi, E.H. Determination of some bioactive chemical constituents from Thesium humile Vahl. J. Mater. Environ. Sci. 2015, 6, 2778–2783. [Google Scholar]
  48. Akpuaka, A.; Ekwenchi, M.M.; Dashak, D.A.; Dildar, A. Biological activities of characterized isolates of n-hexane extract of Azadirachta indica A. Juss (Neem) leaves. Nat. Sci. 2013, 11, 141–147. [Google Scholar]
  49. Brooks, J.D.; Milne, G.L.; Yin, H.; Sanchez, S.C.; Porter, N.A.; Morrow, J.D. Formation of highly reactive cyclopentenone isoprostane compounds (A3/J3-isoprostanes) in vivo from eicosapentaenoic acid. J. Biol. Chem. 2008, 283, 12043–12055. [Google Scholar] [CrossRef]
  50. Jiang, J.; Oberdörster, G.; Biswas, P. Characterization of size, surface charge, and agglomeration state of nanoparticle dispersions for toxicological studies. J. Nanoparticle Res. 2009, 11, 77–89. [Google Scholar] [CrossRef]
  51. Ali, S.W.; Joshi, M.; Rajendran, S. Synthesis and characterization of chitosan nanoparticles with enhanced antimicrobial activity. Int. J. Nanosci. 2011, 10, 979–984. [Google Scholar] [CrossRef]
  52. Santo Pereira, A.E.; Silva, P.M.; Oliveira, J.L.; Oliveira, H.C.; Fraceto, L.F. Chitosan nanoparticles as carrier systems for the plant growth hormone gibberellic acid. Colloids Surf. B. Biointerfaces 2017, 150, 141–152. [Google Scholar] [CrossRef]
  53. Hejjaji, E.M.; Smith, A.M.; Morris, G.A. Evaluation of the mucoadhesive properties of chitosan nanoparticles prepared using different chitosan to tripolyphosphate (CS: TPP) ratios. Int. J. Biol. Macromol. 2018, 120, 1610–1617. [Google Scholar] [CrossRef]
  54. Barrera-Necha, L.L.; Correa-Pacheco, Z.N.; Bautista-Baños, S.; Hernández-López, M.; Jiménez, J.E.M.; Mejía, A.F.M. Synthesis and characterization of chitosan nanoparticles loaded botanical extracts with antifungal activity on Colletotrichum gloeosporioides and Alternaria species. Adv. Microbiol. 2018, 8, 286. [Google Scholar] [CrossRef]
  55. Guo, H.; Li, F.; Qiu, H.; Liu, J.; Qin, S.; Hou, Y.; Wang, C. Preparation and characterization of chitosan nanoparticles for chemotherapy of melanoma through enhancing tumor penetration. Front. Pharmacol. 2020, 11, 317. [Google Scholar] [CrossRef] [PubMed]
  56. Elisa, F.R.; Taís, T.; de Barros, A.; Assis, O.B.G.; Junior, A.C.; Quiles, A.; Hernando, I.; Nicoletti, V.R. Chitosan and crosslinked chitosan nanoparticles: Synthesis, characterization and their role as Pickering emulsifiers. Carbohydr. Polym. 2020, 250, 116878. [Google Scholar]
  57. Müller, R.H.; Jacobs, C.; Kayser, O. Nanosuspensions as particulate drug formulations in therapy: Rationale for development and what we can expect for the future. Adv. Drug Deliv. Rev. 2001, 47, 3–19. [Google Scholar] [CrossRef]
  58. Kumar, A.; Dixit, C.K. Methods for Characterization of Nanoparticles. In Advances in Nanomedicine for the Delivery of Therapeutic Nucleic Acids; Elsevier: Amsterdam, The Netherlands, 2017; pp. 43–58. [Google Scholar]
  59. Huang, J.; Li, Q.; Sun, D.; Lu, Y.; Su, Y.; Yang, X.; Wang, H.; Wang, Y.; Shao, W.; He, N.; et al. Biosynthesis of silver and gold nanoparticles by novel sundried Cinnamomum camphora leaf. Nanotechnology 2007, 18, 105104. [Google Scholar] [CrossRef]
  60. Chandra Hembram, K.; Prabha, S.; Chandra, R.; Ahmed, B.; Nimesh, S. Advances in preparation and characterization of chitosan nanoparticles for therapeutics. Artif. Cells Nanomed. Biotechnol. 2016, 44, 305–314. [Google Scholar] [CrossRef]
  61. Rampino, A.; Borgogna, M.; Blasi, P.; Bellich, B.; Cesàro, A. Chitosan nanoparticles: Preparation, size evolution and stability. Int. J. Pharm. 2013, 455, 219–228. [Google Scholar] [CrossRef]
  62. Gokce, Y.; Cengiz, B.; Yildiz, N.; Calimli, A.; Aktas, Z. Ultrasonication of chitosan nanoparticle suspension: Influence on particle size. Colloids Surf. A Physicochem. Eng. Asp. 2014, 462, 75–81. [Google Scholar] [CrossRef]
  63. Khoerunnisa, F.; Nurhayati, M.; Dara, F.; Rizki, R.; Nasir, M.; Aziz, H.A.; Opaprakasit, P. Physicochemical properties of TPP-crosslinked chitosan nanoparticles as potential antibacterial agents. Fibers Polym. 2021, 22, 2954–2964. [Google Scholar] [CrossRef]
  64. Koukaras, E.N.; Papadimitriou, S.A.; Bikiaris, D.N.; Froudakis, G.E. Insight on the formation of chitosan nanoparticles through ionotropic gelation with tripolyphosphate. Mol. Pharm. 2012, 9, 2856–2862. [Google Scholar] [CrossRef]
  65. Yousefpour, P.; Atyabi, F.; Vasheghani-Farahani, E.; Movahedi, A.M.; Dinarvand, R. Targeted delivery of doxorubicin-utilizing chitosan nanoparticles surface-functionalized with anti-Her2 trastuzumab. Int. J. Nanomed. 2011, 6, 1977–1990. [Google Scholar] [CrossRef] [PubMed]
  66. Corazzari, I.; Nisticò, R.; Turci, F.; Faga, M.G.; Franzoso, F.; Tabasso, S.; Magnacca, G. Advanced physicochemical characterization of chitosan by means of TGA coupled on-line with FTIR and GCMS: Thermal degradation and water adsorption capacity. Polym. Degrad. Stab. 2015, 112, 1–9. [Google Scholar] [CrossRef]
  67. Kittur, F.; Prashanth, K.H.; Sankar, K.U.; Tharanathan, R. Characterization of chitin, chitosan and their carboxymethyl derivatives by differential scanning calorimetry. Carbohydr. Polym. 2002, 49, 185–193. [Google Scholar] [CrossRef]
  68. Norizadeh Tazehkand, M.; Topaktas, M.; Yilmaz, M.B.; Hajipour, O.; Valipour, E. Delineating the antigenotoxic and anticytotoxic potentials of 4-methylimidazole against ethyl methanesulfonate toxicity in bone marrow cell of Swiss albino mice. Bratisl. Med. J. 2016, 9248, 290–294. [Google Scholar] [CrossRef]
  69. Müller, L.; Gocke, E.; Lavé, T.; Pfister, T. Ethyl methanesulfonate toxicity in Viracept—A comprehensive human risk assessment based on threshold data for genotoxicity. Toxicol. Lett. 2009, 190, 317–329. [Google Scholar] [CrossRef] [PubMed]
  70. Zhu, X.; Huo, J.; Zeng, Z.; Liu, Y.; Li, R.; Chen, Y.; Zhang, L.; Chen, J. Determination of potential thresholds for N-ethyl-N-nitrosourea and ethyl methanesulfonate based on a multi-endpoint genotoxicity assessment platform in rats. Environ. Sci. Pollut. Res. 2022, 29, 85128–85142. [Google Scholar] [CrossRef]
  71. Yan, W.; Deng, X.W.; Yang, C.; Tang, X. The genome-wide EMS mutagenesis bias correlates with sequence context and chromatin structure in rice. Front. Plant Sci. 2021, 12, 579675. [Google Scholar] [CrossRef]
  72. Mohamed, N.R.; Badr, T.M.; Elnagar, M.R. Efficiency of curcumin and chitosan nanoparticles against toxicity of potassium dichromate in male mice. Int. J. Pharm. Pharm. Sci. 2021, 13, 22159. [Google Scholar] [CrossRef]
  73. Hamdan, D.I.; Tawfeek, N.; El-Shiekh, R.A.; Khalil, H.M.; Mahmoud, M.Y.; Bakr, A.F.; Zaafar, D.; Farrag, N.; Wink, M.; El-Shazly, A.M. Salix subserrata bark extract-loaded chitosan nanoparticles attenuate neurotoxicity induced by sodium arsenate in rats in relation with HPLC–PDA-ESI–MS/MS profile. AAPS PharmSciTech 2022, 24, 15. [Google Scholar] [CrossRef]
  74. Hamouda, R.A.; Salman, A.S.; Alharbi, A.A.; Alhasani, R.H.; Elshamy, M.M. Assessment of the Antigenotoxic Effects of Alginate and ZnO/Alginate–Nanocomposites Extracted from Brown Alga Fucus vesiculosus in Mice. Polymers 2021, 13, 3839. [Google Scholar] [CrossRef] [PubMed]
  75. Sinitsky, M.Y.; Kutikhin, A.G.; Tsepokina, A.V.; Shishkova, D.K.; Asanov, M.A.; Yuzhalin, A.E.; Minina, V.I.; Ponasenko, A.V. Mitomycin C induced genotoxic stress in endothelial cells is associated with differential expression of proinflammatory cytokines. Mutat. Res./Genet. Toxicol. Environ. Mutagen. 2020, 858, 503252. [Google Scholar] [CrossRef] [PubMed]
  76. Sharifi-Rad, M.; Anil Kumar, N.V.; Zucca, P.; Varoni, E.M.; Dini, L.; Panzarini, E.; Rajkovic, J.; Tsouh Fokou, P.V.; Azzini, E.; Peluso, I.; et al. Lifestyle, oxidative stress, and antioxidants: Back and forth in the pathophysiology of chronic diseases. Front. Physiol. 2020, 11, 694. [Google Scholar] [CrossRef]
  77. Moharram, B.A.; Al-Mahbashi, H.M.; Saif-Ali, R.; AliAqlan, F. Phytochemical, anti-inflammatory, antioxidant, cytotoxic and antibacterial study of Capparis cartilaginea decne from Yemen. Int. J. Pharm. Pharm. Sci. 2018, 10, 38. [Google Scholar] [CrossRef]
  78. He, J.R.; Zhu, J.J.; Yin, S.W.; Yang, X.Q. Bioaccessibility and intracellular antioxidant activity of phloretin embodied by gliadin/sodium carboxymethyl cellulose nanoparticles. Food Hydrocoll. 2022, 122, 107076. [Google Scholar] [CrossRef]
  79. Hu, Y.; Lin, Q.; Zhao, H.; Li, X.; Sang, S.; McClements, D.J.; Long, J.; Jin, Z.; Wang, J.; Qiu, C. Bioaccessibility and bioavailability of phytochemicals: Influencing factors, improvements, and evaluations. Food Hydrocoll. 2022, 108165. [Google Scholar] [CrossRef]
  80. Abdel-Wahhab, M.A.; Aljawish, A.; El-Nekeety, A.A.; Abdel-Aziem, S.H.; Hassan, N.S. Chitosan nanoparticles plus quercetin suppress the oxidative stress, modulate DNA fragmentation and gene expression in the kidney of rats fed ochratoxin A-contaminated diet. Food Chem. Toxicol. 2017, 99, 209–221. [Google Scholar] [CrossRef] [PubMed]
Pharmaceutics 15 02551 g001
Figure 1. Schematic representation of the CNP synthesis process.
Figure 1. Schematic representation of the CNP synthesis process.
Pharmaceutics 15 02551 g001
Pharmaceutics 15 02551 g002
Figure 2. Schematic representation of the CNP/Cc synthesis process.
Figure 2. Schematic representation of the CNP/Cc synthesis process.
Pharmaceutics 15 02551 g002
Pharmaceutics 15 02551 g003
Figure 3. FTIR spectroscopy of C. cartilaginea (a), CNPs (b), and CNPs/Cc (c).
Figure 3. FTIR spectroscopy of C. cartilaginea (a), CNPs (b), and CNPs/Cc (c).
Pharmaceutics 15 02551 g003
Pharmaceutics 15 02551 g004
Figure 4. GC–MS analysis of ethanol extracts of C. cartilaginea plant.
Figure 4. GC–MS analysis of ethanol extracts of C. cartilaginea plant.
Pharmaceutics 15 02551 g004
Pharmaceutics 15 02551 g005
Figure 5. Zeta potential of CNPs/Cc (a) and CNPs (b).
Figure 5. Zeta potential of CNPs/Cc (a) and CNPs (b).
Pharmaceutics 15 02551 g005
Pharmaceutics 15 02551 g006
Figure 6. TEM image of CNPs (a) and CNPs/Cc (b).
Figure 6. TEM image of CNPs (a) and CNPs/Cc (b).
Pharmaceutics 15 02551 g006
Pharmaceutics 15 02551 g007aPharmaceutics 15 02551 g007b
Figure 7. Energy-dispersive X-ray spectrophotometry analysis of CNPs (a) and CNPs/Cc (b).
Figure 7. Energy-dispersive X-ray spectrophotometry analysis of CNPs (a) and CNPs/Cc (b).
Pharmaceutics 15 02551 g007aPharmaceutics 15 02551 g007b
Pharmaceutics 15 02551 g008
Figure 8. DSC of CNPs (a) and CNPs/Cc (b).
Figure 8. DSC of CNPs (a) and CNPs/Cc (b).
Pharmaceutics 15 02551 g008
Table 1. Experimental design and animal groups.
Table 1. Experimental design and animal groups.
GroupsTreatment and DosesTreatment Day(s)
ControlControl (negative)1
EMS:intraperitoneal single injection with 240 mg/kg b.w
CNPs:oral administration with 350 mg/kg b.w. of chitosan nanoparticle
HD of CNPs/Cc:oral administration with 700 mg/kg b.w. of CNPs loaded with C. cartilaginea
LD of CNPs/Cc:oral administration with 350 mg/kg b.w. of CNPs loaded with C. cartilaginea
CNPs + EMSCNPs (350 mg/kg b.w.) + EMS (single injection with 240 mg/kg b.w)
HD of CNPs/Cc +EMS(single injection with 240 mg/kg b.w)
LD of CNPs/Cc + EMS(single injection with 240 mg/kg b.w)
ControlControl (negative)7
EMS:intraperitoneal single injection with 240 mg/kg b.w, 24 h before the experiment.
CNPs:oral administration with 350 mg/kg b.w. of chitosan nanoparticle
HD of CNPs/Cc:oral administration with 700 mg/kg b.w. of CNPs loaded with C. cartilaginea
LD of CNPs/Cc:oral administration with 350 mg/kg b.w. of CNPs loaded with C. cartilaginea
CNPs + EMSCNPs (350 mg/kg b.w.) + EMS (single injection with 240 mg/kg b.w)
HD of CNPs/Cc +EMS(single injection with 240 mg/kg b.w)
LD of CNPs/Cc + EMS(single injection with 240 mg/kg b.w)
Table 2. C. cartilaginea, CNPs, and CNPs/Cc analysis by FTIR.
Table 2. C. cartilaginea, CNPs, and CNPs/Cc analysis by FTIR.
Wavenumber cm−1PlantCNP/CcCNPsFunctional GroupsRef.
3346.88NdDNdHydroxyl groups[29]
3335.45NdNdDStretching N-H asymmetric[30]
3231.22DNdNdO-H bond stretching[31]
2132.35NdD−6Si–H stretching[29]
1636.33−38DDCHO stretching of carbonyl group[30]
1558.81NdNdDC–C stretch aromatic rings (phenolic)[32]
1540.41−22DDAmide II[30]
1418.53−21D+39Deformation C–H[30]
1267.27+NdNdC-O stretching[33]
1077.43NdD+19C=C bond[34]
1011.96+17DNdC-F groups[28]
950.72NdDNdAmines[35]
614.09DNd+9C–S stretch[36]
D: detected, Nd: not detected, (−): shifted wavenumber by minus, (+): shifted wavenumber by addition.
Table 3. GC–MS analysis of C. cartilaginea extract.
Table 3. GC–MS analysis of C. cartilaginea extract.
Biological Activity Molecular WeightMolecular FormulaChemical StructureArea %Compound NameRT
Antimicrobial, Anti-inflammatory, Antioxidant [37]152C9H12O2Pharmaceutics 15 02551 i0014.257-Hydroxy-bicyclo[3.3.1]n on-2-en-9-one5.53
Antimicrobial, Anti-inflammatory, Antioxidant [37]152C9H12O2Pharmaceutics 15 02551 i0026.157-HYDROXY-BICYCLO[3.3.1]N ON-2-EN-9-ONE5.58
Anticancer agent [38]129C5H7NO3Pharmaceutics 15 02551 i0039.03D-Pyroglutamic acid6.50
Acetohydrazides and acetamides possessed anticancer agents [39]196C10H16N2O2Pharmaceutics 15 02551 i0042.05Acethydrazide, n2-[1-(2,3-dihydro-6-methyl pyran-2-yl)ethylideno]-7.14
Analgesic, digestive, and wound healing [40]
Agonist activity at human TRPA1 channel expressed in HEK293 cell [41]		150C10H14OPharmaceutics 15 02551 i0052.003,5-Heptadienal, 2-ethylidene-6-methyl-13.36
The main compounds are found in Kei Apple fruits and have antioxidant and anticancer activities [42]157C2H7NO3S2Pharmaceutics 15 02551 i0062.982-AMINOETHANETHIOL HYDROGEN SULFATE (ESTER)24.73
Hepatoprotective Antiandrogenic, Antihistaminic, Anticoronary, Insectifuge, Anticancer [43]298C18H31ClOPharmaceutics 15 02551 i0072.769,12-Octadecadienoyl chloride, (Z,Z)-25.07
Anti-oxidant, decreases blood cholesterol, anti-inflammatory [44]270C17H34O2Pharmaceutics 15 02551 i00811.79Hexadecanoic acid, methyl ester26.13
Antimicrobial [45]284C18H36O2Pharmaceutics 15 02551 i0093.09Hexadecanoic acid, ethyl ester27.39
Antibacterial [46]282C18H34O2Pharmaceutics 15 02551 i0103.219-Octadecenoic acid (z)-, hexadecanoic acid27.84
Antioxidant, anticancer [44,47]296C19H36O2Pharmaceutics 15 02551 i0112.099-Octadecenoic acid (Z)-, methyl ester29.31
Antimicrobial [48]298C19H38O2Pharmaceutics 15 02551 i0123.24Octadecanoic acid, methyl ester29.82
Antibacterial, Anti-inflammatory, cancer preventive, hepatoprotective, nematicide, insectifuge [45]292C19H32O2Pharmaceutics 15 02551 i01314.999,12,15-Octadecatrienoic acid, methyl ester30.54
Antibacterial [46]282C18H34O2Pharmaceutics 15 02551 i0142.919-OCTADECENOIC ACID (Z)- 2-AMINOETHANETHIOL30.96
Anti-atherosclerotic, anti-inflammatory, and anti-proliferative effects [49]302C20H30O2Pharmaceutics 15 02551 i015
21,736,059.79		3.22cis-5,8,11,14,17-Eicosapentaenoic acid43.76
Table 4. Number and mean percentage of the different types of chromosomal aberrations in mouse bone marrow cells after treatment with different doses of CNPs/Cc and CNPs alone or in combination with EMS.
Table 4. Number and mean percentage of the different types of chromosomal aberrations in mouse bone marrow cells after treatment with different doses of CNPs/Cc and CNPs alone or in combination with EMS.
Treatment No. of Metaphases with Aberrations Chromosomal Aberrations
GapFrag. and/or BreakGap + (Frag. or Break)DeletionRingTotal No.Excluding Gaps Mean ± S.E.Including Gaps Mean ± S.E.Inhibition %
One-day treatments
Control2400060.8 ± 0.41.2 ± 0.4
EMS20622810212220.4 ± 0.7 a24.4 ± 0.4 a
CNPs109500243.6 ± 0.484.8 ± 0.4
HD of CNPs/Cc125220214.6 ± 0.24.2 ± 0.2
LD of CNPs/Cc133610234.2 ± 0.34.106 ± 0.4
CNPs + EMS14503311010818.8 ± 0.3721.6 ± 0.7 a11.4
HD of CNPs/Cc + EMS116115919717.2 ± 0.3719.4 ± 0.6 a20.49
LD of CNPs/Cc + EMS2251330010616.8 ± 0.6 a21.2 ± 0.6 a13.1
Seven-day treatments
Control2400060.8 ± 0.41.2 ± 0.1
EMS20622810212220.4 ± 0.7 a24.4 ± 0.4 a
CNPs123520232.2 ± 0.2 4.6 ± 0.6
HD of CNPs/Cc125300201.6 ± 0.4 4.0 ± 0.1
LD of CNPs/Cc1210000222.0 ± 0.4 4.4 ± 0.4
CNPs + EMS2039111208212.4 ± 0.6 ab16.4 ± 0.7 ab32.7
HD of CNPs/Cc + EMS1227470507.6 ± 0.5 ab10 ± 0.8 ab59.01
LD of CNPs/Cc + EMS182432407812 ± 0.7 ab15.6 ± 0.7 ab36.06
a: Significant at 0.01 level (t-test) compared to control (non-treated). b: Significant at 0.01 level (t-test) compared to treatment (EMS).
Table 5. Number and percentage of different types of sperm shape abnormalities in male mice after treatment with different doses of CNPs/Cc and CNPs alone or in combination with EMS.
Table 5. Number and percentage of different types of sperm shape abnormalities in male mice after treatment with different doses of CNPs/Cc and CNPs alone or in combination with EMS.
Treatment and Doses (mg/kg b.wt.)Sperm No.No. of Sperm with Abnormalities inAbnormal Sperm No.Abnormal Sperm Mean % ± S.E.Inhibition %
HeadTail
AmorphousTringleWithout HookSmallBigCoiled
Control5000293628006991.98 ± 0.1
EMS5000259183473122972214.4 ± 1.78 a
CNPs5000312560024861.72 ± 0.24
HD of CNPs/Cc5000253250021831.66 ± 0.2
LD of CNPs/Cc5000322170035951.9 ± 0.9
CNPs + EMS5000204109192016750110.02 ± 0.98 ab30.6
HD of CNPs/Cc + EMS5000158932372803637.26 ± 0.56 ab49.7
LD of CNPs/Cc + EMS500010613030412144859.7 ± 0.22 ab32.8
a: Significant at 0.01 level (t-test) compared to control (non-treated). b: Significant at 0.01 level (t-test) compared to treatment (EMS).
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Salman, A.S.; Alkhatib, S.N.; Ahmed, F.M.; Hamouda, R.A. Chitosan Nanoparticles Loaded with Capparis cartilaginea Decne Extract: Insights into Characterization and Antigenotoxicity In Vivo. Pharmaceutics 2023, 15, 2551. https://doi.org/10.3390/pharmaceutics15112551

AMA Style

Salman AS, Alkhatib SN, Ahmed FM, Hamouda RA. Chitosan Nanoparticles Loaded with Capparis cartilaginea Decne Extract: Insights into Characterization and Antigenotoxicity In Vivo. Pharmaceutics. 2023; 15(11):2551. https://doi.org/10.3390/pharmaceutics15112551

Chicago/Turabian Style

Salman, Asmaa S., Shaza N. Alkhatib, Fatimah M. Ahmed, and Ragaa A. Hamouda. 2023. "Chitosan Nanoparticles Loaded with Capparis cartilaginea Decne Extract: Insights into Characterization and Antigenotoxicity In Vivo" Pharmaceutics 15, no. 11: 2551. https://doi.org/10.3390/pharmaceutics15112551

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop